Ionis Pharmaceuticalsの空売り状況は、投資家がIonis Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Ionis Pharmaceuticals (NASDAQ:IONS) 株価情報, 空売り情報

IONIS PHARMACEUTICALS INC

Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals Inc

<ul>
<li>The Company had previously announced its intention to explore all strategic options for the Display business and to classify the Display business as discontinued operations when it reports Q1 results in May in order to focus as a pure-play Power discrete and Power IC company and to achieve profitable revenue growth and maximize shareholder value.&nbsp;</li>
<li>However, the Company has not been able to consummate a transaction following several months of discussions with several interested parties on terms that the Company's Board of Directors believed were in the best interests of the Company and its stockholders. Therefore, the Company has already begun notifying its customers impacted by this decision.&nbsp;</li>
</ul>

News

General

Magnachip Semiconductor Approved A Plan To Shut Down The Company's Display Business By The End Of The Second Quarter Of 2025

Guidance

TLRY

Tilray Brands Cuts FY25 Revenue Guidance From $950M - $1B To $850M - $900M Vs. $893.060M Est.

UCAR

UCAR Unveils UOTTA Battery Swap Station In Bangkok, Launching First Operational Ecosystem In Southeast Asia With SUSCO

As major indices have moved into the oversold territory, led by the tariff-fueled selloff over the last three sessions, CNBC&#8217;s Jim Cramer has questioned the Tuesday up move in futures.
What Happened: &#8220;What a tough moment,&#8221; said Cramer in an X post, who is the host of CNBC's ‘Mad Money&#8217;.
According to him, the market looks technically ready for a bounce due to being oversold, and futures point to a strong open. However, the lack of clear positive news making the futures surge might make investors cautious about buying into this initial strength.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">What a tough moment. We are so oversold and the futures are so high that buying here is a very difficult chore. We have been there before and the market can be a coiled spring without news
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1909513930080149729?ref_src=twsrc%5Etfw">April 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In the following X post, he also questioned whether buyers were discounting <a href="https://www.benzinga.com/markets/25/04/44677506/china-resolutely-opposes-trumps-50-tariff-threat-vows-countermeasures-as-trade-tensions-jolt-markets?_gl=1kzrvdi_gcl_auNzQyMjgxNjUuMTczNzYwNzI4NQ.._gaZGVsZXRlZA.._ga_V7ZK73W7N0&#x2A;MTc0NDEwMDY0OS4yNDkuMC4xNzQ0MTAwNjQ5LjAuMC4w">China&#8217;s retaliatory tariffs</a> that could worsen the state of the economy. Cramer wonders if the current buying is rational or it &#8220;is all a big trap?&#8221; He&#8217;s cautious about buying into the current positive momentum after successfully avoiding panic selling the day before.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Are the buyers gambling that it doesn&#39;t matter if we put another 50 on China, that stocks are that low? Or is is all a big trap? We succeeded in not selling into yesterday&#39;s panic. But can we really buy into today&#39;s euphoria?
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1909515797115842722?ref_src=twsrc%5Etfw">April 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks">Wall Street Eyes Recovery As S&amp;P 500, Nasdaq Futures Rise After Trump&#8217;s Tariff-Driven Selloff Wipes Out $9 Trillion In Six Weeks</a>
Why It Matters: The technical analysis of the exchange-traded funds tracking the S&amp;P 500 and the Nasdaq 100 indices, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), shows that both of them have slipped into the oversold zone.
According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, SPY was trading below its short and long-term simple daily moving averages, and its momentum indicator signaled a bearish trend with a negative 14.73 MACD line.
Its relative strength index at 23.11 was below the threshold of 30, indicating that it was in the oversold territory and could be poised for a bounce back.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-1024x576.png" alt="" class="wp-image-861561" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Similarly, QQQ was also below its short and long-term moving averages, having a negative MACD line of 16.90, suggesting a bearish trend. Its RSI at 28.59 was also in the oversold zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-1024x576.png" alt="" class="wp-image-861566" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Cramer, in an earlier post, also expressed skepticism about Monday's post-market <a href="https://www.benzinga.com/markets/equities/25/04/44677995/jim-cramer-says-market-rebound-feels-strange-after-nine-nights-of-losses-things-arent-better-as-stock-futures-surge-over-1">futures rebound</a>, calling it "strange" following nine consecutive down days in futures trading.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We don&#39;t want to se the futures up this much. So strange. We have come in down every night for 9 nights. Now the futures are up huge. Where are the sellers. Things aren&#39;t &quot;better&quot; now unless we are at levels people, at last, like.
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1909410023681204517?ref_src=twsrc%5Etfw">April 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: As of Monday, the S&amp;P 500 was 17.65% below its previous record high of 6,147.43 points. The Nasdaq 100 continued to hover in the bear market territory, 21.56% lower from its previous high of 22,222.61 points. The Dow Jones, on the other hand, was down by 15.77% from its 52-week high of 45,073.63 points.
In premarket on Tuesday, the SPY was up 1.28% to $510.85, while the QQQ advanced 1.06% to $428.17, according to Benzinga Pro data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44679385/market-enters-risk-off-mode-as-analyst-predicts-this-signal-flashing-warnings-similar-to-2020-and-2008-crisis" target="_blank" rel="noreferrer noopener">Market Enters ‘Risk-Off' Mode As Analyst Predicts This Signal Flashing Warnings Similar To 2020, 2008 Crisis</a></li>
</ul>
Image via Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Technicals

Economics

Markets

Analyst Ratings

Trading Ideas

ETFs

Jim Cramer Cautions Against Jumping In As Oversold Market Sparks Futures Rebound Without Clear Catalyst: 'Is It All A Big Trap?'

Transaction Expected to Help TRNR Generate More than $65M in 2025 Revenue on a Pro Forma basis
Wattbike is the Leading, Indoor-Bike Brand for Elite-Athlete Training and is Used by Olympians and Professional Sports Teams Worldwide - Including the NFL, NBA, MLB, NHL and Premier League
TRNR Listing, Global Distribution Network to Help Wattbike Accelerate Growth, Especially in Key Markets Like US and Germany; Wattbike's Deep Penetration into Leading UK Gyms and Expanding D2C Customer Base to Similarly Speed Up Step-Changes to TRNR Top and Bottom Lines
Transaction Delivers on Previously-Announced LOI, Combines Highly Complementary Businesses to Create a Scaled, International Operation Anchored in the US, Germany and UK, the #1, <a href="https://interactivestrength.com/germany-spotlight/">#2</a> and <a href="https://interactivestrength.com/uk-market-distribution/">#3 Fitness Markets</a> Globally
Deal - Expected to be TRNR's 3rd Within a Year-and-a-Half - Builds on its Transformative Portfolio Strategy for Creating Long-Term Shareholder Value
Acquisition Expected to Close as Early as the Second Quarter of 2025, Subject to Standard Regulatory Requirements
 &nbsp;

New ETFs

TRNR

Interactive Strength Expands Global Footprint With Wattbike Acquisition, Targeting Over $65M In 2025 Pro Forma Revenue

<ul>
<li>After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12</li>
<li>Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12</li>
<li>Safety profile consistent with previously reported data and continues to support outpatient administration</li>
<li>Phase 3 AURORA trial on track to dose first patient in 2Q25</li>
</ul>

Biotech

Health Care

RNAC

Cartesian Therapeutics Announced 12-month Efficacy And Safety Data From Phase 2b Trial Of Descartes-08 In Participants With Generalized Myasthenia Gravis. Participants Dosed With A Single Six-week Course Of Treatment Of Descartes-08 Were Observed To Continue To Experience A Sustained Benefit In Symptoms

Jefferies analyst David Windley upgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Underperform to Hold and raises the price target from $53 to $64.

Upgrades

Price Target

Jefferies Upgrades Centene to Hold, Raises Price Target to $64

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy rating and announces Price Target of $2.5.

Initiation

VNRX

HC Wainwright & Co. Initiates Coverage On VolitionRX with Buy Rating, Announces Price Target of $2.5

HUM: 16% &#x7C; <a href="https://www.benzinga.com//node/44674240">Shares of health insurers are trading higher following a WSJ report indicating the Trump administration will increase payment rates for Medicare insurers.</a>
&nbsp;
MRVL: 7% &#x7C; <a href="https://www.benzinga.com//node/44680589">Marvell Technology shares are trading higher after Infineon Technologies agreed to acquire its Automotive Ethernet Business for $2.5 billion in cash.</a>
&nbsp;
NYXH: 62% &#x7C; <a href="https://www.benzinga.com//node/44678177">Nyxoah Nears FDA Approval For Genio System Following Approvable Letter Confirming PMA Requirements Are Substantially Met</a>

Movers

MRVL

NYXH

Market-Moving News for April 8th

Revised Fiscal Year 2025 Guidance
The Company revised the following fiscal year guidance. This guidance is on a pro forma basis, excluding the full fiscal year financial impact of certain of the homecare and cleaning products classified as assets held for sale and the impact of the uncertain tax position benefit.
<ul>
<li>Net sales growth from the pro-forma 2024 results continues to be projected to be between 6 and 11 percent with net sales between $600 million and $630 million after adjusting for estimated translation impacts of foreign currency.</li>
<li>Gross margin for the full year has been increased and is now expected to be between 55 and 56 percent.</li>
<li>Advertising and promotion investments continue to be projected to be around 6 percent of net sales.</li>
<li>Operating income continues to be projected to be between $95 million and $100 million. This range reflects anticipated growth of between 6 to 12 percent compared to 2024 pro forma results.</li>
<li>The provision for income tax has been reduced and is expected to be around 22.5 percent.</li>
<li>Diluted earnings per share have been increased and are now expected to be between $5.25 and $5.55 based on an estimated 13.5 million weighted average shares outstanding. This new range reflects anticipated growth of between 11 to 17 percent compared to 2024 pro forma results.</li>
</ul>

WDFC

WD-40 Company Reiterates FY25 Guidance For Net Sales At $600M-$630M, 6%-11% Growth Vs $627.1M, Raised Outlook For EPS To $5.25-$5.55 (From $5.20-$5.45) Vs $5.42 Est.

THTX

The FDA Approved Theratechnologies' Prior Approval Supplement To The Supplemental Biologics License Application For Egrifta SV (Tesamorelin For Injection). Tesamorelin For Injection Is Approved In The Us To Reduce Excess Abdominal Fat In Adults With HIV And Lipodystrophy

Jefferies analyst Peter Abramowitz initiates coverage on Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) with a Buy rating and announces Price Target of $150.

Jefferies Initiates Coverage On Sun Communities with Buy Rating, Announces Price Target of $150

Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) reported quarterly sales of $185.78 million which missed the analyst consensus estimate of $210.45 million by 11.72 percent. This is a 1.36 percent decrease over sales of $188.34 million the same period last year.

Earnings

Earnings Misses

Tilray Brands Q3 Sales $185.78M Miss $210.45M Estimate

Stock markets endured <a href="https://www.benzinga.com/hedge-funds/25/04/44676150/ceos-wall-street-titans-brace-for-sustained-market-downturn-theres-too-much-confidence-in-the-system">major swings this week</a>, with futures rising in after-hours trading on Monday after a volatile session. A brief rally was prompted by hopes of a delay in new tariffs, but those hopes were quickly dashed. Meanwhile, GameStop CEO Ryan Cohen, a vocal Trump supporter, is making headlines for his reaction to the <a href="https://www.benzinga.com/markets/25/04/44678625/did-trump-team-manipulate-tariff-formula-to-achieve-higher-rates-experts-weigh-in-as-they-think-whole-thing-was-rigged">latest developments.</a>
What Happened: Cohen, who has publicly expressed his support for Donald Trump through several posts on X, published a sarcastic comment in response to the latest round of U.S. tariffs: "I can't wait for my $10,000 made in the USA iPhone." 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I can't wait for my $10,000 made in the USA IPhone
&mdash; Ryan Cohen (@ryancohen) <a href="https://twitter.com/ryancohen/status/1908204902456656225?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
His remark came on the heels of <a href="https://www.benzinga.com/25/04/44677880/apple-reportedly-plans-to-move-more-iphone-production-to-india-amid-trump-tariff-fearscould-this-solve-the-300-price-hike-on-550-hardware">reports that electronics prices could increase</a> significantly due to the trade uncertainties, with Reuters approximating iPhone prices could climb by as much as 43%.
See Also: <a href="https://www.benzinga.com/markets/25/04/44656119/trump-tariffs-could-blow-up-apple-analyst-estimates-39-5-billion-impact">&#8216;Trump Tariffs Could Blow Up Apple&#8217;: Analyst Estimates $39.5 Billion Impact</a>
Why It Matters: The new tariffs are already impacting consumer goods and tech launches. Nintendo announced a postponement in pre-orders for its upcoming Switch 2, referencing the need to assess the "potential impacts of tariffs and evolving market conditions." For GameStop, a major retailer of consoles like the Switch, that delay could have <a href="https://www.benzinga.com/25/04/44672218/gamestop-enters-the-danger-zone-death-cross-flashes-but-ryan-cohen-isnt-flinching">noteworthy revenue implications</a>. Cohen's viral reaction highlights the tension between political support and business consequences.
As the market continues to react to changing trade policy, CEOs like Cohen are discovering themselves at the center of the conversation. His online remarks, while made seemingly in jest, reflect the wider concerns over how tariffs may impact consumer prices and shape corporate strategy moving forward.
Read Next: <a href="https://www.benzinga.com/news/25/04/44677532/howard-lutnick-says-army-of-millions-will-build-iphones-in-the-us-but-could-trumps-tariffs-make-the">Howard Lutnick Says Army Of Millions Will Build iPhones In The US, But Could Trump&#8217;s Tariffs Make The Premium Apple Flagship Cost $2,300?</a>
Image via Shutterstock

GameStop CEO Ryan Cohen's Support For Trump Faces New Test After He Posts '$10,000 iPhone' Tweet Amid Market Turmoil And Tariff Fallout

Given The Pending Transaction Pursuant To Which Walgreens Boots Alliance Will Be Acquired By Sycamore Partners, The Company Is Withdrawing Fiscal 2025 Guidance

WD-40 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.27 by 3.94 percent. The company reported quarterly sales of $146.10 million which missed the analyst consensus estimate of $154.41 million by 5.38 percent. This is a 5.03 percent increase over sales of $139.10 million the same period last year.

Earnings Beats

WD-40 Q2 2025 Adj EPS $1.32 Beats $1.27 Estimate, Sales $146.10M Miss $154.41M Estimate

Jefferies analyst Peter Abramowitz initiates coverage on Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) with a Buy rating and announces Price Target of $80.

Jefferies Initiates Coverage On Equity Lifestyle Props with Buy Rating, Announces Price Target of $80

Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares are trading higher premarket on Tuesday.
On Monday, the company disclosed a definitive deal to sell its Automotive Ethernet business to Infineon Technologies AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IFNNY#OTC">IFNNY</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44674510/marvell-to-sell-automotive-ethernet-business-to-infineon-for-2-5-billion-in-cash" rel="noreferrer noopener">for $2.5 billion in an all-cash deal</a>.
The transaction includes Marvell's Brightlane Automotive Ethernet portfolio and related assets.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44674813/if-tariffs-shift-customer-spending-priorities-these-software-stocks-could-face-slow-growth" rel="noreferrer noopener">If Tariffs Shift Customer Spending Priorities, These Software Stocks Could Face Slow Growth</a>
The company projected this segment to generate $225 million to $250 million in revenue in 2025, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44678709/infineon-further-strengthens-its-number-one-position-in-automotive-microcontrollers-and-boosts-sys" rel="noreferrer noopener">with a gross margin of around 60%</a>.
Approved by Marvell's Board of Directors, the deal is expected to close by the end of 2025, pending regulatory approvals and standard closing conditions.
Matt Murphy, Chairman and CEO of Marvell said, "We believe this transaction delivers the strongest financial return for Marvell shareholders, given its compelling valuation."
Jochen Hanebeck, CEO of Infineon added, "We will leverage this highly complementary Ethernet technology by combining it with our existing, broad product portfolio to provide our customers with even more comprehensive, leading solutions for software-defined vehicles."
"The transaction will support our profitable growth strategy going forward, including new opportunities in the field of physical AI such as humanoid robots."
Last month, the company and TeraHop debuted PCIe Gen 6 over optics to boost AI data center speed and scalability at the Optical Networking and Communication <a target="_blank" href="https://www.benzinga.com/25/03/44517705/marvell-launches-next-gen-connectivity-to-meet-rising-ai-demands-in-data-infrastructure" rel="noreferrer noopener">Conference and Exposition (OFC)&nbsp;2025</a>.
Investors can gain exposure to MRVL via&nbsp;Spear Alpha ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRX#NASDAQ">SPRX</a>) and Innovator Deepwater Frontier Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOUP#NYSE">LOUP</a>).
Price Action: MRVL shares are up 3.82% at $52.95 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44653936/broadcom-and-marvell-poised-for-growth-as-nvidias-cpo-push-faces-delays-analyst-reveals" target="_blank" rel="noreferrer noopener">Rising Tide Of AI Is So Strong That Semiconductor Optical Industry Projects $30 Billion Total Addressable Market By 2029</a></li>
</ul>
Photo via Shutterstock

Large Cap

Asset Sales

IFNNY

LOUP

SPRX

Marvell Offloads Auto Ethernet Segment To Infineon Tech For $2.5 Billion Cash

UNH REVERSES EARLY WEAKNESS ON SIGNAL &amp; CLIMBS OVER 20 POINTS
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/07210750/Screenshot-2025-04-07-at-5.01.56%E2%80%AFPM-940x1024.png" alt="" class="wp-image-9971" /></figure>
UnitedHealthcare Group, Inc. (UNH) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:04 AM on April 7th, a significant trading signal occurred for UnitedHealthcare Group, Inc. (UNH) as it demonstrated a Power Inflow at a price of $507.54. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in UNH&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in UNH&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for UNH, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like    <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>, which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE: The price at the time of the Power Inflow was $507.54. The returns on the High price ($529.17) and Close price ($524.70) after the Power Inflow are respectively 4.3% and 3.4%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Performance Not Indicative of Future Results

WIIM

Signals

UnitedHealth Stock Up Over 4% After Key Signal, Amid Market Turmoil

Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.53 by 18.87 percent. This is a 47.5 percent decrease over earnings of $1.20 per share from the same period last year. The company reported quarterly sales of $38.59 billion which beat the analyst consensus estimate of $38.00 billion by 1.55 percent. This is a 4.15 percent increase over sales of $37.05 billion the same period last year.

Walgreens Boots Alliance Q2 2025 Adj EPS $0.63 Beats $0.53 Estimate, Sales $38.59B Beat $38.00B Estimate

Press Releases

Ionis to hold fourth quarter and full year 2024 financial results webcast

Ionis reports fourth quarter and full year 2024 financial results

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

Ionis to present at upcoming investor conferences

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Comments

Ionis Pharmaceuticals

空売り

Ionis Pharmaceuticals (NASDAQ:IONS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル